VYVGART Hytrulo NDC 73475-1221

NDC codes

FDA NDC Directory

Product NDC (as listed)73475-1221Labeler and product segments. Claims need a package NDC.

Product NDC at billing width73475-1221Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
73475-1221-1	73475122101	1 SYRINGE, GLASS in 1 CARTON (73475-1221-1) / 5 mL in 1 SYRINGE, GLASSMarketed from Apr 10, 2025
73475-1221-4	73475122104	4 SYRINGE, GLASS in 1 CARTON (73475-1221-4) / 5 mL in 1 SYRINGE, GLASSMarketed from Apr 10, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): VYVGART Hytrulo
Generic name (nonproprietary): efgartigimod alfa and hyaluronidase (human recombinant)
Active ingredients: Efgartigimod alfa — 200 mg/mLHyaluronidase (Human recombinant) — 2000 U/mL
Dosage form: Injection, Solution
Route: Subcutaneous
Labeler: argenx US
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761304
Marketing start: Apr 10, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Glycoside Hydrolases (Chemical structure)Neonatal Fc Receptor Blockers (Mechanism)
Identifiers: Product ID 73475-1221_a2607d4b-76e8-4004-94c2-190fdc8593fbSPL ID a2607d4b-76e8-4004-94c2-190fdc8593fbSPL set ID 7104d9e5-9910-47f5-9a93-741ac50f43b6RxCUI 2639951, 2639957, 2712083, 2712088UNII 961YV2O515, 743QUY4VD8
Pharmacologic class: Endoglycosidase; Neonatal Fc Receptor Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N473475122101 followed by a unit qualifier and the quantity

Package 73475-1221-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 15, 2026.

Indications (excerpt from the label)

VYVGART HYTRULO is indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) chronic inflammatory demyelinating polyneuropathy (CIDP) VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) ( 1 ) chronic inflammatory demyelinating polyneuropathy (CIDP) ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 761304

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761304
Product	Strength	Form · route	Labeler	Product NDC
VYVGART Hytruloefgartigimod alfa and hyaluronidase (human recombinant)	Efgartigimod alfa 180 mg/mL; Hyaluronidase (Human recombinant) 2000 U/mL	Injection, SolutionSubcutaneous	argenx US	73475-3102